[go: up one dir, main page]

MX2018009908A - Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos. - Google Patents

Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos.

Info

Publication number
MX2018009908A
MX2018009908A MX2018009908A MX2018009908A MX2018009908A MX 2018009908 A MX2018009908 A MX 2018009908A MX 2018009908 A MX2018009908 A MX 2018009908A MX 2018009908 A MX2018009908 A MX 2018009908A MX 2018009908 A MX2018009908 A MX 2018009908A
Authority
MX
Mexico
Prior art keywords
group
hydrogen atom
strogen
dihidro
benzo
Prior art date
Application number
MX2018009908A
Other languages
English (en)
Other versions
MX380091B (es
Inventor
El-Ahmad Youssef
Brollo Maurice
Schio Laurent
Bouaboula Monsif
Certal Victor
Filoche-Rommé Bruno
Halley Frank
Mccort Gary
Tabart Michel
Terrier Corinne
Thompson Fabienne
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2018009908A publication Critical patent/MX2018009908A/es
Publication of MX380091B publication Critical patent/MX380091B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I): (ver Fórmula) en donde R1 y R2 representan átomos de hidrógeno o deuterio; R3 representa un átomo de hidrógeno o un grupo -COOH, -OH u - OPO(OH)2; R4 representa un átomo de hidrógeno o un átomo de flúor; R5 representa un átomo de hidrógeno o un grupo -OH; en donde al menos uno de R3 o R5 es diferente de un átomo de hidrógeno; cuando R3 representa un grupo -COOH, -OH u - OPO(OH)2, entonces R5 representa un átomo de hidrógeno; cuando R5 representa un grupo -OH, entonces R3 y R4 representan átomos de hidrógeno; y R6 se selecciona entre un grupo fenilo, heteroarilo, cicloalquilo o heterocicloalquilo opcionalmente sustituido. La invención se refiere también a la preparación y a los usos terapéuticos de los compuestos de fórmula (I) como inhibidores y degradadores de los receptores de estrógeno, útiles especialmente en el tratamiento del cáncer.
MX2018009908A 2016-02-15 2017-02-14 Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrógenos. MX380091B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305174 2016-02-15
PCT/EP2017/053282 WO2017140669A1 (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

Publications (2)

Publication Number Publication Date
MX2018009908A true MX2018009908A (es) 2018-09-07
MX380091B MX380091B (es) 2025-03-11

Family

ID=55398242

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009908A MX380091B (es) 2016-02-15 2017-02-14 Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrógenos.
MX2020011469A MX386677B (es) 2016-02-15 2017-02-14 Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011469A MX386677B (es) 2016-02-15 2017-02-14 Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos

Country Status (37)

Country Link
US (7) US9714221B1 (es)
EP (2) EP3524600B1 (es)
JP (4) JP6425852B1 (es)
KR (2) KR102813742B1 (es)
CN (2) CN108884079B (es)
AR (1) AR107616A1 (es)
AU (2) AU2017221083B2 (es)
BR (1) BR112018016490A2 (es)
CA (1) CA3014424A1 (es)
CL (1) CL2018002290A1 (es)
CO (1) CO2018009534A2 (es)
CR (1) CR20180442A (es)
CY (1) CY1125165T1 (es)
DK (2) DK3524600T3 (es)
DO (1) DOP2018000184A (es)
EA (2) EA034994B1 (es)
EC (1) ECSP18069466A (es)
ES (2) ES2906208T3 (es)
HR (1) HRP20211043T1 (es)
HU (2) HUE055107T2 (es)
IL (2) IL261099B (es)
LT (1) LT3416962T (es)
MA (2) MA46479A (es)
MX (2) MX380091B (es)
MY (2) MY196486A (es)
PE (1) PE20181893A1 (es)
PH (1) PH12018501679A1 (es)
PL (1) PL3416962T3 (es)
PT (1) PT3416962T (es)
RS (1) RS62132B1 (es)
SG (2) SG10202106024XA (es)
SI (1) SI3416962T1 (es)
TN (1) TN2018000285A1 (es)
TW (3) TWI779621B (es)
UY (1) UY37124A (es)
WO (1) WO2017140669A1 (es)
ZA (1) ZA201805137B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813742B1 (ko) * 2016-02-15 2025-05-28 사노피 에스트로겐 수용체 조절자로서의 6,7-디하이드로-5h-벤조[7]아눌렌 유도체
ES3039455T3 (en) * 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
KR102765922B1 (ko) 2018-02-06 2025-02-11 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
CN113490850B (zh) 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
CN112638869B (zh) * 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
EP3699167A1 (en) 2019-02-22 2020-08-26 Sanofi Process for preparing methyl 1-benzosuberone-7-carboxylate
MX2021013711A (es) * 2019-05-09 2021-12-10 Sanofi Sa Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.
KR102058384B1 (ko) * 2019-09-06 2019-12-24 강원대학교산학협력단 2h-벤조[7]에눌렌 화합물 및 이의 제조방법
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
US12528768B2 (en) 2019-12-09 2026-01-20 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN113896669B (zh) * 2020-06-22 2024-12-17 海南先声再明医药股份有限公司 雌激素受体调节剂及其用途
CN115916769B (zh) * 2020-06-28 2024-09-10 深圳扬厉医药技术有限公司 并环吲唑类化合物
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
CN116615414A (zh) * 2020-10-19 2023-08-18 赛诺菲 经取代的6,7-二氢-5h-苯并[7]轮烯化合物及其衍生物、其制备方法及其治疗用途
CN116782895A (zh) * 2020-11-23 2023-09-19 赛诺菲 包含阿贝西利和6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸的组合
EP4247977A2 (en) 2020-11-23 2023-09-27 Sanofi Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
EP4289841A4 (en) * 2021-02-04 2025-02-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
TW202304425A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202304424A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
TW202313558A (zh) * 2021-07-08 2023-04-01 大陸商勤浩醫藥(蘇州)有限公司 一類苯并七元環類化合物及其應用
WO2023287938A1 (en) 2021-07-15 2023-01-19 Teva Pharmaceuticals International Gmbh Solid state forms of amcenestrant
WO2023125700A1 (zh) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
TW202400136A (zh) 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
JP2025512050A (ja) 2022-04-15 2025-04-16 サノフイ 新規の置換された４－アミノ－４－オキソ－ブト－２－エニル誘導体、それらの調製のためのプロセス及びその治療的使用
US20250248970A1 (en) 2022-04-15 2025-08-07 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
US20250255848A1 (en) 2022-04-15 2025-08-14 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
US20250263390A1 (en) 2022-04-15 2025-08-21 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
JP2025513063A (ja) 2022-04-15 2025-04-22 サノフイ 新規置換フッ化ビニル－ｎ－プロピル－ピロリジン化合物、それを調製するためのプロセス及びその治療的使用
US20250262186A1 (en) 2022-04-15 2025-08-21 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n-propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2024006776A1 (en) * 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
CN119907798A (zh) 2022-08-25 2025-04-29 赛诺菲 新颖的取代的2,3,4,9-四氢-1h-吡啶并[3,4-b]吲哚甲酸衍生物、其制备方法及其治疗用途
JP2025531033A (ja) 2022-08-25 2025-09-19 サノフイ 新規の置換２－カルボニル－ベンゾチオフェン－６－カルボン酸誘導体、それらの調製のためのプロセス及びその治療的使用
CN119790048A (zh) 2022-08-25 2025-04-08 赛诺菲 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途
CN119744261A (zh) 2022-08-25 2025-04-01 赛诺菲 新颖的经取代的喹啉和四氢化萘甲酸衍生物及其治疗用途
CN119768396A (zh) 2022-08-25 2025-04-04 赛诺菲 新颖的取代的苯并噻吩-6-羧酸衍生物、其制备方法及其治疗用途
EP4584257A1 (en) 2022-09-09 2025-07-16 Sanofi Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
CN120615091A (zh) * 2023-01-16 2025-09-09 正大天晴药业集团股份有限公司 取代的苯并七元环化合物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506467A (ja) * 1991-03-08 1994-07-21 ローヌ−プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286893T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
EP1417169A2 (en) * 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
EP1577288B1 (en) 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Selective estrogen receptor modulators
CA2824106A1 (en) * 2003-08-29 2005-03-10 Ono Pharmaceutical Co., Ltd. Compound capable of binding s1p receptor and pharmaceutical use thereof
MX2007000036A (es) * 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
US20050288238A1 (en) * 2004-06-28 2005-12-29 Pfizer Inc Benzocyclodecane derivatives with antitumor activity
DE102005014090A1 (de) * 2005-03-22 2006-09-28 Schering Ag 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
JP5354775B2 (ja) * 2005-06-14 2013-11-27 ベイラー ユニバーシティ チューブリン結合活性を有するコンブレタスタチンアナログ
EP2048126A1 (de) * 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
EP2090579A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted heteroarylamide diazepinopyrimidone derivatives
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) * 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
TW201329025A (zh) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
JP2015504049A (ja) * 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドＣｅｎｔａｕｒｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用
AP2015008673A0 (en) * 2013-02-19 2015-08-31 Bayer Pharma Aktiengesellchaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
WO2015028409A1 (de) * 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN112375077A (zh) 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
SG10202104177VA (en) 2015-04-29 2021-05-28 Radius Pharmaceuticals Inc Methods of treating cancer
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
KR102813742B1 (ko) * 2016-02-15 2025-05-28 사노피 에스트로겐 수용체 조절자로서의 6,7-디하이드로-5h-벤조[7]아눌렌 유도체
ES3039455T3 (en) 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
BR112018016490A2 (pt) 2018-12-18
DK3524600T3 (da) 2022-02-07
TWI779621B (zh) 2022-10-01
ES2906208T3 (es) 2022-04-13
SG10202106024XA (en) 2021-07-29
MY206566A (en) 2024-12-21
JP2019031537A (ja) 2019-02-28
IL277750B (en) 2022-06-01
UY37124A (es) 2017-09-29
LT3416962T (lt) 2021-07-12
EP3524600A1 (en) 2019-08-14
EP3524600B1 (en) 2021-11-17
CN112979524B (zh) 2024-09-10
PL3416962T3 (pl) 2021-11-22
CO2018009534A2 (es) 2018-09-20
EA201891841A1 (ru) 2019-01-31
AU2021225215B2 (en) 2023-05-25
US11214541B2 (en) 2022-01-04
KR20220098057A (ko) 2022-07-08
EP3416962A1 (en) 2018-12-26
JP6425852B1 (ja) 2018-11-21
SI3416962T1 (sl) 2021-08-31
CR20180442A (es) 2018-12-21
MY196486A (en) 2023-04-17
MA46479A (fr) 2019-08-14
TWI737681B (zh) 2021-09-01
US9714221B1 (en) 2017-07-25
TW202138349A (zh) 2021-10-16
CN108884079B (zh) 2021-03-05
EA034994B1 (ru) 2020-04-15
AU2017221083B2 (en) 2021-06-24
EP3416962B1 (en) 2021-05-05
US20180079720A1 (en) 2018-03-22
MX380091B (es) 2025-03-11
CL2018002290A1 (es) 2018-10-05
AU2021225215A1 (en) 2021-09-30
EA202090255A2 (ru) 2020-05-31
KR102813742B1 (ko) 2025-05-28
MA44226B1 (fr) 2021-07-29
IL277750A (en) 2020-11-30
KR20180105759A (ko) 2018-09-28
JP6695457B2 (ja) 2020-05-20
AU2017221083A1 (en) 2018-10-04
IL261099A (en) 2018-10-31
DK3416962T3 (da) 2021-07-26
CA3014424A1 (en) 2017-08-24
KR102813741B1 (ko) 2025-05-28
HUE055107T2 (hu) 2021-10-28
MX2020011469A (es) 2021-09-30
TW202138348A (zh) 2021-10-16
IL261099B (en) 2020-10-29
PT3416962T (pt) 2021-07-23
JP6476343B2 (ja) 2019-02-27
US10570090B2 (en) 2020-02-25
JP6868142B2 (ja) 2021-05-12
CY1125165T1 (el) 2023-06-09
TWI779620B (zh) 2022-10-01
ECSP18069466A (es) 2018-09-30
HRP20211043T1 (hr) 2021-10-01
JP2018537406A (ja) 2018-12-20
US20200392081A1 (en) 2020-12-17
AR107616A1 (es) 2018-05-16
PH12018501679A1 (en) 2019-06-10
TW201741285A (zh) 2017-12-01
JP2020128385A (ja) 2020-08-27
JP2019081776A (ja) 2019-05-30
ES2881508T3 (es) 2021-11-29
TN2018000285A1 (en) 2020-01-16
EA038639B1 (ru) 2021-09-28
MX386677B (es) 2025-03-19
ZA201805137B (en) 2023-09-27
PE20181893A1 (es) 2018-12-11
CN112979524A (zh) 2021-06-18
US20170233340A1 (en) 2017-08-17
DOP2018000184A (es) 2019-01-31
WO2017140669A1 (en) 2017-08-24
RS62132B1 (sr) 2021-08-31
CN108884079A (zh) 2018-11-23
US20240150284A1 (en) 2024-05-09
US20210323916A1 (en) 2021-10-21
US20250368605A1 (en) 2025-12-04
US20220073460A1 (en) 2022-03-10
HUE057892T2 (hu) 2022-06-28
SG11201806829TA (en) 2018-09-27
EA202090255A3 (ru) 2020-07-31

Similar Documents

Publication Publication Date Title
MX2018009908A (es) Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos.
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
MX377124B (es) Compuestos heterociclicos y usos de los mismos.
PE20161251A1 (es) Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4
NZ716840A (en) Combination formulation of two antiviral compounds
CO2019002692A2 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
EA201490726A1 (ru) Фармацевтические соединения для применения в терапии инфекции clostridium difficile
PE20160556A1 (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
AR103316A1 (es) Inhibidores de dihidroquinazolina de terminasa viral
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
AR093168A1 (es) COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1
PE20180658A1 (es) Sintesis total de shishijimicina a y sus analogos
CU24134B1 (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, y las composiciones farmacéuticas que los contienen
BR112014019476A8 (pt) Novos derivados de imidazolilcetona
AR078672A1 (es) Derivados de dihidropirrolonaftiridinonas inhibidores de quinasas jak, composiciones farmaceuticas que los contienen y uso de los mismos para tratar procesos inmunologicos, canceres y otras patologias.